@article{silverberg_upadacitinib_2022,
 author = {Silverberg, Jonathan I. and Bruin-Weller, Marjolein de and Bieber, Thomas and Soong, Weily and Kabashima, Kenji and Costanzo, Antonio and Rosmarin, David and Lynde, Charles and Liu, John and Gamelli, Amy and Zeng, Jiewei and Ladizinski, Barry and Chu, Alvina D. and Reich, Kristian},
 doi = {10.1016/j.jaci.2021.07.036},
 file = {Silverberg et al. - 2022 - Upadacitinib plus topical corticosteroids in atopi.pdf:files/2751/Silverberg et al. - 2022 - Upadacitinib plus topical corticosteroids in atopi.pdf:application/pdf;Snapshot:/Users/axelbudde/Zotero/storage/5BJ5YSJX/fulltext.html:text/html},
 issn = {0091-6749, 1097-6825},
 journal = {Journal of Allergy and Clinical Immunology},
 keywords = {-100, -75, -90, ≥75%, ≥90%, 100%, AD, Adverse event, AE, Atopic dermatitis, BE, Blinded extension, Coronavirus disease 2019, COVID-19, CPK, Creatine phosphokinase, EASI, EASI-50, Eczema Area and Severity Index, Herpes zoster, HZ, Improvement from baseline in EASI of ≥50%, JAK, Janus kinase, Janus kinase inhibitors, Least squares mean, LSM, MI, Multiple imputation, Nonresponse imputation incorporating MI to handle missing data due to COVID-19, NRI-C, Patient-year, PBO, Placebo, PY, RA, randomized clinical trial, Rheumatoid arthritis, TCS, TEAE, Topical corticosteroid, topical corticosteroids, Treatment-emergent adverse event, upadacitinib, Validated Investigator’s Global Assessment for AD of clear or almost clear with ≥2 grades of improvement, vIGA-AD 01, Worst Pruritus Numerical Rating Scale, WP-NRS},
 language = {English},
 month = {March},
 note = {Publisher: Elsevier},
 number = {3},
 pages = {977--987.e14},
 pmid = {34403658},
 shorttitle = {Upadacitinib plus topical corticosteroids in atopic dermatitis},
 title = {Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results},
 url = {https://www.jacionline.org/article/S0091-6749(21)01212-4/fulltext},
 urldate = {2022-05-29},
 volume = {149},
 year = {2022}
}

